Status:
UNKNOWN
Prediction of Metaphase II Oocytes According to Different Levels of Serum AMH in Poor Responders Using the Antagonist Protocol
Lead Sponsor:
Cairo University
Conditions:
Invitro Fertilizaion
Eligibility:
FEMALE
20-45 years
Phase:
NA
Brief Summary
A multicentric study looked into 179 poor responders who underwent antagonist protocol in ICSI cycles Gonadotrophines is started on day 2 with HMG until the day of HCG administration with starting dos...
Detailed Description
A multicentric study looked into 179 poor responders who underwent antagonist protocol in ICSI cycles Induction of ovulation cycle: 1. Gonadotrophines is started on day 2with HMG(merional, IBSA) ,un...
Eligibility Criteria
Inclusion
- 3- On antagonist protocol 4- Poor responder according to ESHRE consensus; in which at least 2 of the following should be present:
- Advanced maternal age (≥ 40 years old) or any other risk factor
- A previous poor ovarian response (cycles cancelled or ≤ 3 oocytes with a conventional protocol)
- An abnormal ovarian reserve test (ORT); antral follicle count (AFC) \< 5-7 follicles or anti-mullerian hormone (AMH) ≤0.5- 1.1 ng/ml NB: In the absence of advanced maternal age or abnormal ORT, two previous episodes of poor ovarian response after maximal stimulation patients are also considered poor responders according to ESHRE consensus.
- Presence and Adequate visualization of both ovaries
- Uterine cavity within normal anatomy
Exclusion
- Any factor which may affect reproductive outcome other than that the patient is a poor responder will be excluded from the study, like:
- Severe male factor .
- Uterine factor (eg: fibroid, polyp, Ashermann, .. etc)
- Immunological disorder (eg: SLE, APS, … etc)
- Thyroid or adrenal dysfunction
- Neoplasia (especially: hypothalamic, pit, ovarian)
- Women diagnosed with PCOS according to Rotterdam criteria
- Hydrosalpinx that hasn't been surgically removed or ligated. 8 . Untreated hyperprolactinemia 9 . Abnormal bleeding disorder
- Hepatic or renal dysfunction 11.Hypersenstivity to study medication ( GNRH antagonist) 12.Need to take medication that can influence ovarian stimulation 13.Endometriosis grade 3 or 4 14.Ovarian cyst\> 10 cm.
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2018
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT03484611
Start Date
January 1 2013
End Date
April 1 2018
Last Update
April 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr Alainy medical school
Cairo, Egypt, 12111